Blade Air Mobility, Inc.

Company Overview

Business Model: Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company offers an integrated "one call" solution for donor organ recovery, operating one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations. Core services, marketed under the Trinity Medical Solutions and Keystone Perfusion Services, LLC brands, include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion, and preservation for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers. The Company's mission is to increase the number of organs successfully transplanted while expanding its medical and logistics services to a broader customer base.

Market Position: Strata Critical Medical, Inc. competes in highly competitive and rapidly evolving markets, including organ transportation and logistics, aviation operations, healthcare service provision, and transplant logistics coordination. The Company differentiates itself through its technology-enabled service, access to a wide variety of aircraft types (jets, turboprops, helicopters) for efficient organ transport, and its ability to provide skilled clinical practitioners with a lower cost structure and greater reliability than internal hospital resources. The Company's integrated offering, combining logistics and clinical services, aims to streamline communication and enhance efficiency for customers.

Recent Strategic Developments:

• Divestiture of Passenger Business: On August 29, 2025, the Company completed the sale of its legacy Passenger mobility business to Joby Aero, Inc., a wholly owned subsidiary of Joby Aviation, Inc. This transaction resulted in a strategic shift, allowing Strata Critical Medical, Inc. to focus exclusively on medical logistics and clinical services. The Company received approximately $75.4 million in consideration, primarily in Joby Aviation, Inc. common stock, which was subsequently sold for net proceeds of $70.2 million. The Company may receive up to an additional $35.0 million in contingent consideration based on financial performance and employee retention targets.
• Acquisition of Keystone Perfusion Services, LLC: On September 16, 2025, the Company acquired Keystone Perfusion Services, LLC, an organ recovery and normothermic regional perfusion service provider. This acquisition launched the Company's Clinical segment, expanding its service offerings to include surgical recovery, normothermic regional perfusion, and preservation services, enhancing its end-to-end solution for the transplant industry. The upfront payment included $111.3 million in cash and 3,434,609 shares of common stock (valued at $16.8 million).
• Rebranding: Following the divestiture, the Company rebranded from Blade Air Mobility, Inc. to Strata Critical Medical, Inc., reflecting its focused strategy on critical medical services.
• Aircraft Acquisition: In 2024, the Company acquired ten fixed-wing aircraft dedicated to its Logistics segment, moving towards a hybrid asset-light and asset-ownership model to improve economies of scale, increase uptime, and compete for contracts requiring asset ownership.

Geographic Footprint: Strata Critical Medical, Inc. operates exclusively within the United States healthcare industry. Its corporate headquarters is in New York, New York, with a 24/7/365 operations center in Chandler, Arizona. Clinical segment staff and equipment are distributed at or near supporting hospitals and Organ Procurement Organizations, with some transplant clinical staff and equipment positioned at air logistics hubs across key airports in Bedford, Massachusetts; Teterboro, New Jersey; Scottsdale, Arizona; Madison, Wisconsin; and Denver, Colorado.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 20.9%
• Operating Margin: -11.3%
• Net Margin: -10.2%

Investment in Growth (2025):

• R&D Expenditure (Software Development): $3.1 million (1.5% of revenue)
• Capital Expenditures: $9.6 million (primarily for a spare engine, aircraft capitalized maintenance, and ground logistics vehicles)
• Strategic Investments:
  • Acquisition of Keystone Perfusion Services, LLC: $111.3 million in cash and $16.8 million in equity consideration upfront, with potential earn-out payments up to $23.0 million.
  • Purchase of an additional aircraft: $3.8 million (agreement in January 2026, $0.2 million deposit paid in 2025).

Business Segment Analysis

Logistics Segment

Financial Performance (2025):

• Revenue: $176.8 million (+20.4% YoY)
• Gross Profit: $36.6 million (+23.8% YoY)
• Operating Margin (Gross Margin): 20.7% (21% as stated in MD&A)
• Key Growth Drivers: Growth in flight hours, ground transportation, and revenue per trip, driven by both existing and new contracted clients commencing operations in Q2 2025. Operational leverage in ground services with the expansion of ground hubs also contributed to margin improvement.

Product Portfolio:

• Air Logistics: Air transportation of human organs, staff, equipment, blood, and tissue samples, typically on fixed-wing aircraft. Also offers on-board couriers for commercial flights and "next flight out" shipping coordination.
• Ground Logistics: Ground transportation of human organs, staff, equipment, blood, and tissue samples.
• Organ Placement (TOPS): Administrative services for evaluating potential donor organs and coordinating the transplant process.

Market Dynamics:

• Competitive positioning: Competes primarily with Part 135 jet operators and asset-light logistics businesses based on technology-enabled service and access to diverse aircraft types.
• Key customer types: Transplant centers, organ procurement organizations, and other businesses, often on a contractual "first call" basis.
• Market trends: Rapidly evolving with new organ preservation technology; some manufacturers of proprietary devices now offer bundled logistics and clinical services.

Clinical Segment

Financial Performance (2025):

• Revenue: $20.3 million (new segment in 2025, no prior year revenue)
• Gross Profit: $4.5 million
• Operating Margin (Gross Margin): 22.1% (22% as stated in MD&A)
• Key Growth Drivers: The acquisition of Keystone Perfusion Services, LLC in mid-September 2025.

Product Portfolio:

• Transplant Clinical: Surgical procurement of donor organs (Organ Recovery), in situ perfusion of donor organs (Normothermic Regional Perfusion - NRP), and operation of preservation devices (Preservation).
• Other Clinical: Cardiac perfusion, blood management & autotransfusion, disposables, Extracorporeal Membrane Oxygenation (ECMO) services, perfusion temporary staffing, and equipment rental for healthcare providers.

Market Dynamics:

• Competitive positioning: Competes with internal hospital/OPO resources and other clinical service providers, primarily on the ability to consistently provide skilled clinical practitioners with a lower cost structure and more reliability.
• Key customer types: Organ procurement organizations (OPOs) and transplant centers for transplant-related services, and cardiac care hospitals for other clinical services.
• Market trends: High demand for skilled clinicians (perfusionists, organ recovery surgeons) due to growth in these fields.

Sub-segment Breakdown (2025):

• Transplant clinical: $9.0 million revenue
• Other clinical: $11.4 million revenue

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No repurchases in 2025. The share repurchase program expired on March 31, 2025.
• Dividend Payments: The Company has never declared or paid cash dividends on its common stock and has no intention to do so in the foreseeable future.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $31.0 million
• Total Debt: $0 (no debt on balance sheet as of December 31, 2025)
• Net Cash Position: $31.0 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Subsequent to year-end, in January 2026, the Company entered into a secured asset-based revolving credit facility (ABL Facility) of up to $30.0 million, maturing on January 30, 2029. No funds had been drawn as of the filing date.

Cash Flow Generation (2025):

• Operating Cash Flow: $(48.9) million (includes cash flows from discontinued operations)
• Free Cash Flow: Not explicitly provided.
• Cash Conversion Metrics: Not explicitly provided.

Operational Excellence

Production & Service Model: Strata Critical Medical, Inc. operates a hybrid asset-light and asset-ownership model for its air logistics. It primarily utilizes aircraft owned and/or operated by third parties, where pilots, maintenance, hangar, insurance, and fuel costs are borne by the operator network. The Company also owns nine Hawker 800 series midsize jets and has assumed operational control of a tenth, all operated and maintained by third-party service providers under Strata's oversight. Ground logistics are provided using a combination of owned vehicles and third-party providers. Clinical services rely on employed perfusionists and transplant surgeons, primarily dedicated to specific customers, and owned perfusion equipment. The operational philosophy emphasizes an integrated "one call" solution for donor organ recovery, leveraging technology to enhance efficiency and cost-effectiveness.

Supply Chain Architecture: Key Suppliers & Partners:

• Aircraft Operators: Network of third-party operators providing aircraft flight time at fixed hourly rates. Some relationships include Capacity Purchase Agreements (CPAs) with guaranteed flight commitments for dedicated access and lower costs.
• Third-Party Service Providers: Operate and maintain Strata-owned aircraft.
• Ground Transportation Providers: Third-party providers supplement owned vehicles for ground logistics.
• Technology Vendors: Third-party cloud services provider for key technology infrastructure.

Facility Network:

• Corporate Headquarters: New York, New York.
• Operations Center: Chandler, Arizona (24/7/365 staffing for logistics coordination and clinical services).
• Clinical Staff & Equipment Bases: At or near supporting hospitals and Organ Procurement Organizations, with some transplant clinical staff and equipment at air logistics hubs.
• Manufacturing: Not applicable, as the Company provides services.
• Research & Development: Not explicitly detailed beyond software development.
• Distribution: Air logistics hubs in Bedford, Massachusetts; Teterboro, New Jersey; Scottsdale, Arizona; Madison, Wisconsin; and Denver, Colorado. Ground logistics hubs across the United States.

Operational Metrics: The Company prioritizes the use of owned aircraft and dedicated aircraft under CPAs to maximize utilization and achieve better economies of scale, sizing its owned fleet and CPA commitments below expected demand to fulfill incremental demand through non-dedicated operators.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Contractual relationships with transplant centers, organ procurement organizations, and hospitals, often stipulating "first call" for transportation needs.
• Channel Partners: Third-party aircraft operators and ground transportation providers.
• Digital Platforms: Proprietary technology used to manage staffing, training, chain of custody, and to streamline organ evaluation (Trinity Organ Placement Services - TOPS), procurement, and logistics.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Transplant centers, organ procurement organizations, and hospitals.
• Customer Concentration: Three customers, affiliated with the same national hospital group, collectively represented approximately 11% of the Company’s revenues for the year ended December 31, 2025. No single customer accounted for 10% of outstanding accounts receivable as of December 31, 2025.

Geographic Revenue Distribution:

• United States: 100% of total revenue.
• Growth Markets: Not explicitly detailed beyond general expansion within the U.S. healthcare industry.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The organ transplantation industry is highly regulated and rapidly evolving, driven by increasing utilization of Donation after Circulatory Death, advancements in technology (e.g., machine and regional perfusion), and regulatory changes for efficient organ allocation. The supply of donor organs has increased consistently in recent years but has shown recent flattening. The transplant ecosystem in the United States is relatively concentrated among a limited number of transplant centers and OPOs.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Part 135 jet operators: Compete in air logistics.
• Asset-light logistics businesses: Compete in air and ground logistics.
• Transplant centers' and OPOs' internal resources: Compete in organ placement, surgical recovery, NRP, and perfusion staffing.
• Specialty firms: Focused on organ evaluation and coordination.
• Businesses with similar clinical offerings: Compete in surgical recovery, NRP, and perfusion.
• Manufacturers of organ preservation devices: Increasingly offer bundled logistics and clinical services, creating competitive pressure.

Emerging Competitive Threats:

• New entrants: Healthcare providers, aviation operators, technology companies, or device manufacturers.
• Disruptive technologies: Enhanced organ preservation techniques, longer viability windows for donor organs, dedicated organ transport networks using commercial carriers, or the emergence of animal-derived, synthetic, or lab-grown organs.
• Alternative solutions: Competing integrated logistics and clinical service models, proprietary preservation technologies, or differentiated device ecosystems.

Competitive Response Strategy: The Company's strategy includes expanding integrated clinical and logistics offerings, such as the acquisition of Keystone Perfusion Services, LLC, and developing new organic offerings like Trinity Organ Placement Services (TOPS). It focuses on providing high-quality, reliable service with electronic recordkeeping to demonstrate compliance and integrating offerings for streamlined communication and efficient transportation.

Risk Assessment Framework

Strategic & Market Risks

• Continued Net Losses: The Company has incurred significant losses and may continue to do so, with profitability dependent on securing new Medical Customers, asset utilization, and acquisition integration.
• Inability to Realize Anticipated Benefits: Failure to achieve expected cost efficiencies and accretive benefits from the Passenger business divestiture or Keystone acquisition, or to retain Keystone's key employees and clients.
• Reputation and Brand Harm: Negative publicity, litigation, or operational issues could damage the Company's reputation for reliable, safe, and high-quality services.
• Reliance on Contractual Relationships: Dependence on transplant centers, hospitals, OPOs, and strategic partners for a substantial portion of business, with contracts subject to termination or pricing pressure.
• Dependence on Donor Organs: Business is directly tied to the availability and utilization of viable donor organs, which are influenced by factors beyond the Company's control (e.g., donation rates, medical advancements, regulatory changes, public health crises).
• Insufficient Reimbursement/Funding: Customers' inability to secure adequate reimbursement from government programs or private insurers for organ transport and related services could reduce demand.
• Organ Transport Risks: Inherent risks in time-critical organ transport, including delays (weather, air traffic, aircraft availability), improper handling, or equipment malfunctions, leading to liability and reputational damage.
• Ground Transportation Risks: Inherent risks in ground operations (accidents, driver error, weather, equipment failure), regulatory compliance challenges, and potential for increased costs or liability.
• Technology Advancements: New medical preservation technology or improvements in commercial air logistics could reduce demand for private air transportation services.
• Aviation Safety Risks: Inherent risks in aircraft operation, including accidents, incidents, or adverse publicity involving aircraft used in operations, potentially leading to losses, liability, and reduced customer confidence.
• Climate Change: Regulatory developments (emissions, fuel standards) or increased impacts of severe weather events could disrupt operations and increase costs.
• Geopolitical Conflict/Security Events: Terrorist attacks, geopolitical instability, or security incidents could disrupt aviation/healthcare infrastructure, increase costs, or reduce demand.
• Fuel Availability/Cost Volatility: Disruptions in supply or significant increases in aircraft fuel costs could increase operating expenses for operators, affecting the Company's costs and margins.
• Need for Additional Funding: Potential future need for substantial additional capital to fund operations or growth, with no guarantee of availability on acceptable terms.
• Restrictive Covenants: Covenants in the Credit Agreement (entered January 2026) may limit operational or strategic flexibility.
• Future Acquisitions: Risks associated with identifying, financing, and integrating future acquisitions or strategic transactions.

Operational & Execution Risks

• Reliance on Third-Party Providers: Dependence on third-party contractors to provide and operate aircraft, with limited direct control over their operations, leading to potential service disruptions or increased costs.
• Inability to Match Growth in Demand: Third-party aircraft operators may be unable or unwilling to expand capacity to meet demand, or the Company may be unable to add new operators on reasonable terms.
• Workforce Disruptions: Operational interruptions or financial difficulties affecting third-party operators or service providers (e.g., labor shortages, financial distress).
• Improper Operation of Branded Aircraft: Illegal, improper, or inappropriate operation of Strata-owned or Strata-branded aircraft by third-party operators could harm reputation.
• Reliance on Third-Party Web Services: Disruptions or interference with third-party cloud services providers could adversely affect technology systems and operations.
• System Failures/Vulnerabilities: Defects, errors, or vulnerabilities in the Company's or third-party technology systems could harm reputation, disrupt operations, or expose sensitive information.
• Cybersecurity Incidents: Cyberattacks, data breaches, or misuse of artificial intelligence technologies could disrupt operations, expose sensitive information, or lead to increased costs.
• Intellectual Property Protection: Failure to adequately protect proprietary intellectual property rights (trade secrets, trademarks, software copyrights) could impair competitive position.
• Open-Source Software Use: Risks associated with open-source software licenses, potentially requiring disclosure of proprietary source code or containing security vulnerabilities.

Financial & Regulatory Risks

• Highly Regulated Industry: Operations within heavily regulated aviation, healthcare, and transplant environments, subject to evolving federal, state, and local laws (e.g., DOT, FAA, OPTN, HRSA, AKS, FCA, HIPAA).
• Litigation/Regulatory Investigations: Exposure to various litigation and regulatory risks, including class action lawsuits, employment-related claims, or government investigations.
• Privacy and Data Protection: Failure to comply with extensive federal and state privacy and security laws (e.g., HIPAA, CCPA) could result in enforcement actions, fines, or reputational harm.
• Environmental Regulation: Evolving environmental laws and regulations (emissions, fuel usage, noise) could increase costs for the Company or its third-party operators.
• Internal Control Weaknesses: Past identification of material weaknesses in internal control over financial reporting, with a risk of future deficiencies.
• Disclosure Control Failures: Failure to maintain an effective system of disclosure controls and procedures could impair timely and accurate financial statements.
• Warrant Accounting Volatility: Warrants are accounted for as derivative liabilities, with changes in fair value reported in earnings, leading to quarterly fluctuations.
• Stock Price Volatility: The market price of securities may fluctuate significantly due to various factors, including market conditions, investor perception, and industry developments.
• No Dividends: No expectation of declaring dividends in the foreseeable future.
• Dilution from Future Equity: Potential dilution from future issuance of common stock or other equity securities.
• Anti-Takeover Provisions: Provisions in the Company's charter and Delaware law may inhibit takeovers.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Logistics Coordination: Proprietary technology to manage staffing, training, and chain of custody for organ transport.
• Organ Evaluation & Procurement: Technology to help customers streamline organ evaluation (Trinity Organ Placement Services - TOPS) and procurement.
• Clinical Workflow: Technology to enhance the efficiency and cost-effectiveness of service offerings.

Innovation Pipeline: The Company's technology enhances the efficiency and cost-effectiveness of its service offerings, strengthening its position in the organ transportation industry. It responds to customer demand by introducing new services (e.g., Keystone acquisition) and organically adding offerings (e.g., TOPS).

Intellectual Property Portfolio:

• Patent Strategy: Relies primarily on trade secrets and trademarks to protect proprietary technology. Software is subject to copyright law.
• Licensing Programs: Not explicitly detailed.
• IP Litigation: The Company was involved in the Drulias et al. v. Affeldt, et al. class action lawsuit related to the acquisition of Blade Urban Air Mobility, Inc., which was settled in December 2025.

Technology Partnerships: Relies on third-party cloud services providers for key elements of its technology infrastructure.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The former Chief Executive Officer, Robert Wiesenthal, transitioned to Joby Aviation, Inc. following the Passenger business divestiture. The Company's success depends on attracting and retaining highly skilled personnel and senior management.

Board Composition: The Board of Directors has delegated primary responsibility for cybersecurity risk oversight to the Audit Committee. Susan Lyne notified the Board of her decision to resign effective as of the 2026 Annual Meeting of Stockholders, with the Board expecting to reduce its size from nine to eight directors.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 601 (327 full-time, 274 part-time)
• Geographic Distribution: All employees are located across the United States.
• Skill Mix: 223 employees in Logistics, 359 in Clinical, and 19 in headquarters functions. None are represented by a labor union.

Talent Management: Acquisition & Retention: The Company seeks to attract and retain employees with necessary skills and experience, offering competitive compensation and benefits. Its ability to aggregate demand across transplant centers and cardiac care hospitals makes it an attractive employer for clinicians.

• Hiring Strategy: Focuses on hiring, training, and retaining clinicians, particularly perfusionists and organ recovery surgeons.
• Retention Metrics: Not explicitly provided, but the Company emphasizes maintaining its company culture.
• Employee Value Proposition: Competitive compensation and benefits, and a company culture that promotes accountability, attention to detail, communication, and support.

Diversity & Development:

• Diversity Metrics: Not explicitly provided.
• Development Programs: Not explicitly detailed beyond general talent management.
• Culture & Engagement: The Company believes its culture, promoting accountability, attention to detail, communication, and support, has contributed to its success.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: The Company's third-party aircraft operators are subject to various federal, state, and local environmental laws relating to emissions, aircraft noise, fuel usage, and disposal of materials. The Company seeks representations of compliance from its operators. Increased environmental regulation could indirectly increase transportation costs. Supply Chain Sustainability: The Company seeks representations of compliance with applicable environmental laws from its third-party aircraft operators.

Social Impact Initiatives:

• Community Investment: The Company's mission is to increase the number of organs successfully transplanted, aligning its goals with participants in the transplant ecosystem to save more lives.
• Product Impact: Services are designed to improve clinical outcomes and enable functional assessment of donor organs, contributing to successful transplants.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Logistics trip volumes and Clinical case volumes correlate with the overall supply of donor hearts, livers, and lungs in the United States, which can be volatile. The industry has shown modest seasonal softness in the calendar third quarter, though the Company's volumes have not always followed this trend.
• Economic Sensitivity: Not explicitly detailed, but the business is vulnerable to changing market conditions impacting Medical Customers, including hospital budgets and transplant volumes.
• Industry Cycles: Influenced by organ donation rates, advancements in medical practices and preservation technologies, legislative/regulatory changes, and shifts in public attitudes toward organ donation.

Planning & Forecasting: The Company's ability to fulfill time-sensitive requests depends on access to dedicated aircraft and crews, which is a primary metric for customer evaluation.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Transportation and Aviation: Subject to United States Department of Transportation (DOT) regulations as an arranger of air travel and indirect air carrier. Third-party aircraft operators are subject to Federal Aviation Administration (FAA) regulations. Ground transportation is governed by local, state, and federal regulations.
• Healthcare: Operates within a highly regulated framework governed by the National Organ Transplant Act and administered through the Organ Procurement and Transplantation Network (OPTN) under federal oversight by the Health Resources and Services Administration (HRSA). OPOs and hospitals must meet statutory criteria and performance standards.
• Fraud and Abuse Laws: Subject to federal and state healthcare fraud and abuse laws, including the federal Anti-Kickback Statute (AKS), the federal Civil False Claims Act (FCA), and the federal Civil Monetary Penalties Law.
• Privacy and Data Protection: Subject to extensive federal and state privacy and security laws, including the Health Insurance Portability and Accountability Act (HIPAA) and the California Consumer Privacy Act (CCPA), due to processing Protected Health Information (PHI).

Trade & Export Controls: Not explicitly detailed for current business.

Legal Proceedings: The Drulias et al. v. Affeldt, et al. class action lawsuit, filed in February 2024 relating to the acquisition of Blade Urban Air Mobility, Inc., was fully resolved by a Stipulation of Settlement in December 2025, with the Company making the settlement payment into escrow.

Tax Strategy & Considerations

Tax Profile (2025):

• Effective Tax Rate: 0% for continuing operations.
• Geographic Tax Planning: Files tax returns in U.S. federal and various U.S. state and local jurisdictions.
• Tax Reform Impact: As of December 31, 2025, the Company has approximately $78.8 million of gross U.S. federal and $93.6 million of gross U.S. state and local net operating loss (NOL) carryforwards. Federal NOLs incurred from 2018 onwards do not expire, with $66.7 million having an indefinite life. However, $3.3 million of gross federal NOLs are unavailable due to Section 382 ownership changes. A full valuation allowance of $19.2 million is maintained against net deferred tax assets.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains general liability aviation premises insurance, non-owned aircraft liability coverage, directors' and officers' liability insurance, general liability insurance, property insurance, employment practices liability insurance, cyber insurance, and workers' compensation insurance.
• Risk Transfer Mechanisms: Third-party aircraft operators are contractually obligated to indemnify the Company against liability from aircraft operations and maintain specified insurance coverage.